Evaluation of the therapeutic potential of regulatory T cells in lupus

Project 10

Project leader:

PD Dr. med. Nina Babel

CharitéUniversitätsmedizin Berlin

CVK: Campus Virchow-Klinikum

Nephrology and Intensive Medicine and BCRT

Postal address:

Augustenburger Platz 1

13353 Berlin

t: +49 30 450 653 880

f: +49 30 450 553916

Links:

Summary

Regulatory T cells (Treg) are indispensable for the maintenance of peripheral tolerance and thus for the prevention of autoimmunity. Systemic lupus erythematosus (SLE) is an autoimmune disease where Treg fail to control autoimmunity. We could demonstrate that Treg and IL-2 deficiency play a significant role in the pathogenesis of murine lupus. Loss of Treg-mediated tolerance can be restored by adoptive transfer or by their in vivo expansion by IL-2. We optimized treatment protocols with IL-2 and proved the relevance of IL-2 deficiency in human SLE, together providing the rationales to initiate a phase I/IIa clinical study with low dose IL-2 in SLE. Monitoring the TCR repertoire of Treg and conventional T cells in treated and control patients will provide further hints as to the origin and identity of protective cells.

Research Database

For more details please use the Charité undefinedresearch database.